PCSK9 inhibitor

DRUG17 trials

Sponsors

General Hospital of Shenyang Military Region, Jose Seijas Amigo, NYU Langone Health, Shenzhen People's Hospital, Tongji Hospital

Conditions

Acute Coronary SyndromeAcute Coronary SyndromesAcute Ischemic StrokeAcute Myocardial InfarctionAtherosclerosis, CerebralCardiovascular DiseasesCholesterol, LDLCognitive Function

Phase 2

PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy

Not yet recruitingNCT07174375

Nanfang Hospital, Southern Medical UniversityAcute Ischemic Stroke

Start: 2025-09-15End: 2027-12-15Target: 478Updated: 2025-09-15

Phase 4

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

RecruitingNCT03753555

General Hospital of Shenyang Military RegionAtherosclerosis, Cerebral, Stroke, Ischemic

Start: 2018-12-01End: 2026-11-30Target: 100Updated: 2025-03-18

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

CompletedNCT04369664

NYU Langone HealthType 2 Diabetes

Start: 2020-08-12End: 2023-10-19Updated: 2024-10-17

Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

The First Affiliated Hospital with Nanjing Medical UniversityAcute Coronary Syndrome

Start: 2022-04-01End: 2024-04-01Target: 100Updated: 2022-03-28

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients

Active, not recruitingNCT05537948

National Medical Research Center for Therapy and Preventive MedicineDyslipidemias, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemias +3

Start: 2021-10-01End: 2025-01-31Updated: 2025-01-22

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Lin ZhaoIn-stent Restenosis, Major Adverse Cardiovascular Events

Start: 2022-12-15End: 2025-12-01Target: 200Updated: 2023-11-13

Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography

RecruitingNCT06520904

First Affiliated Hospital of Xinjiang Medical UniversityCoronary Artery Disease, Optical Coherence Tomography

Start: 2024-07-01End: 2026-12-31Target: 396Updated: 2024-08-19

Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

Not yet recruitingNCT07084259

Hanyang University Seoul HospitalCoronary Artery Disease

Start: 2025-07-31End: 2030-07-31Target: 352Updated: 2025-07-24

Unknown Phase

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors

CompletedNCT04319081

Jose Seijas AmigoCognitive Function, Hypercholesterolemia, Quality of Life

Start: 2020-03-01End: 2023-01-13Updated: 2023-01-17

Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study

Shenzhen People's HospitalCardiovascular Diseases, Lipid Metabolism

Start: 2021-04-22End: 2023-04-23Target: 100Updated: 2022-05-05

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

RecruitingNCT04847752

Tongji HospitalIschemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)

Start: 2021-03-01End: 2028-12-31Target: 1000Updated: 2024-06-20

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

RecruitingNCT05397405

Nanjing First Hospital, Nanjing Medical UniversityIntracranial Artery Stenosis

Start: 2022-05-23End: 2026-05-01Target: 180Updated: 2024-11-15

Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB

RenJi HospitalHemodialysis Access Failure

Start: 2023-09-10End: 2024-10-01Target: 40Updated: 2023-09-13

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

RecruitingNCT06649240

Seoul National University HospitalCardiovascular Diseases, Cholesterol, LDL, Ischemic Stroke +2

Start: 2024-10-04End: 2030-09-30Target: 4016Updated: 2025-05-21

Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

Not yet recruitingNCT06730802

Nanjing Medical UniversityCoronary Heart Disease, Myocardial Ischaemic Syndrome

Start: 2025-01-01End: 2026-12-31Target: 400Updated: 2024-12-12

Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

RecruitingNCT06738758

Yun Dai ChenAcute Coronary Syndromes

Start: 2024-12-16End: 2027-12-31Target: 6000Updated: 2025-03-17

Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)

Not yet recruitingNCT06854523

Yun Dai ChenAcute Myocardial Infarction

Start: 2025-04-15End: 2026-12-31Target: 300Updated: 2025-03-03

Related Papers

Proactive, short-term PCSK9 inhibition after PCI in patients with coronary artery disease at high residual risk: rationale and design of the randomized HANYANG-PICK trial

Frontiers in Cardiovascular Medicine2026-03-02

A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk.

2025-12-22

Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

Diseases2024-10-053 citations

Abstract 1028: Cytotoxic CD4+ T Cells: Unraveling The Residual Risk In Lipid Lowering For Type 2 Diabetes Patients

Arteriosclerosis Thrombosis and Vascular Biology2024-05-01

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

American Journal of Cardiovascular Drugs2023-08-2310 citations

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients

Frontiers in Cardiovascular Medicine2022-08-098 citations

Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors.

2022-02-033 citations